BUSINESS WIRE
NEW YORK--(BUSINESS WIRE)--Fera Pharmaceuticals is pleased to announce that Bacitracin Ophthalmic
Ointment, USP is now available through wholesalers, chain, independent
and hospital pharmacies.
In July 2009, Fera acquired all rights and title to seven ophthalmic
ointments, including Bacitracin. Product supply has been an issue since
then, as the previous owner had discontinued manufacture of Bacitracin
and only a limited quantity was made available during the transition to
Fera.
“The company has been diligently working to transfer manufacturing of
these products in order to meet market demand for these important
sterile anti-infective ointments” says Frank DellaFera, President of
Fera.
Bacitracin Ophthalmic Ointment, USP is the first product transfer to be
completed. It is anticipated that the transfer of Erythromycin
Ophthalmic Ointment will occur in the next few weeks at which point Fera
would ship immediately.
The manufacturing transfer for the balance of the line is underway with
availability projected later in the year.
About Fera Pharmaceuticals, LLC
Fera Pharmaceuticals is a privately held company. The company goal is
to realize opportunities via acquisitions, in-licensing, developing and
marketing abbreviated new drug applications (ANDAs), new drug
applications (NDAs) and 505(b)(2) NDA products. Areas of interest
include products that could benefit from lifecycle management with a
special focus on niche markets. For more information visit www.ferapharma.com.